We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52061 679 3 CRSP
Emcee:  Biomaven Type:  Moderated
Biotech stocks are a close second only to internet stocks in how difficult they are to objectively value. This means that biotech stocks can be wildly under- or over-valued, which creates an opportunity for either profit or frustration for an investor that "knows better than market." To paraphrase the master: "Every now and again you should look at the stock price to see if the market is offering to do anything stupid."

This thread grew out of the "Munch-a-Biotech" thread, and is meant to discuss biotech stock valuation methods of all sorts, as well as particular stocks or sectors you may feel are under- or over-valued.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
52061Re: another Sell trade on the CRSP core position............... [graphic] TotaOldAIMGuy-May 23
52060Twist Bioscience up 15% on Announcement of a Portfolio of RNA Sequencing Tools, A.J. Mullen1May 22
52059Up another 30% today: Corvus Pharmaceuticals to Present New CPI-818 Data at theAloner-May 17
52058CRVS is up almost 80% in last 5 days of trading: seekingalpha.comAloner1May 15
52057Re: CRSP......... I've only owned CRSP about a year now. It's been a roOldAIMGuy-May 11
52056Positive Individualized Pancreatic Cancer Vaccine news from BioNTech: nature.coAloner3May 11
52055It's up 33% now. I listened to the call. They are partnered with San DiegoA.J. Mullen-May 9
52054Voyager Therapeutics up 20% today, the day they published earnings, finance.yahoA.J. Mullen-May 9
52053There still are a lot of questions concerning efficacy of any treatment for betaArt Bechhoefer1May 5
52052Meanwhile speculation on the old ELAN team of alzheimers researchers at PRTA (PrLance Bredvold-May 5 pros and cons of donanemab, lecanemab, and aducanumab. questions,software salesperson2May 4
52050This is interesting. The results across a number of metrics look remarkably simA.J. Mullen1April 25
52049I listened to the IONS presentation on eplontersen. The 35 and 66 week data werArt Bechhoefer-April 25
52048Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairmeA.J. Mullen-April 25
52047Michael Milken on Bioscience investing (essentially his book promotion): financAloner-April 11
52046The research paper published in the March 17 issue of Science provided details oArt Bechhoefer1March 27
52045Owning some Regeneron stock, I was happy to read effusive quotes from a couple oA.J. Mullen1March 25
52044As I mentioned, don't follow them closely. This is just a research paper. ThJamesK-March 25
52043Re: IONS An article in Science, the weekly journal of the AAAS, dated March 17,Art Bechhoefer2March 24
52042For at least 20 years, the administrative costs associated with health care in tArt Bechhoefer1March 23
52041Today’s NYT has an article on doctor burnout: nytimes.comDewDiligence_on_SI-March 23
520402 topics that have captured my interest lately: 1) Medical billing and 2) PE insoftware salesperson1March 23
52039Regeneron Pharmaceuticals, Inc. Sat, March 18, 2023 at 7:00 AM PDT More than twA.J. Mullen1March 19
52038One small biotech that dodged a bullet: From OMER earnings report this afternooThe Ox-March 13
52037PRVB to be acquired by Sanofi at $25.00/Share, up 258% today Sanofi SA (NASDAQ:Aloner3March 13
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):